《新股表现》创胜(06628.HK)收13.24元低上市价17% 每手账面蚀1,380元

AAFN2021-09-29

创胜集团-B 首日挂牌，股价持续「潜水」，今天低开18.8%报13元，高低见13.34/12.08元，全日收13.24元，较上市价16元，低2.76元或17%，成交1,107万股，涉资1.43亿元。不计手续费，每手500股，账面蚀1,380元。创胜是一家集发现、研发、制造及业务拓展能力为一体临床阶段生物制药公司，管理团队主要业务(包括临床开发、监管准入及业务拓展)位於中国及美国。集团利用高效监管...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2171298543?lang=zh_CN&edition=full","thumbnail":"https://static.tigerbbs.com/6ad7ed6b96b448ffcc5b5501b0dc346c","is_english":false,"pubTime":"2021-09-29 16:14","share_image_url":"https://static.laohu8.com/51f6b9126f36f92bbf92982596066e5a","id":"2171298543","market":"us","top_or_hot":-1,"title":"《新股表现》创胜(06628.HK)收13.24元低上市价17%  每手账面蚀1,380元","media":"AAFN","content":"<div>\n<p>创胜集团-B  首日挂牌，股价持续「潜水」，今天低开18.8%报13元，高低见13.34/12.08元，全日收13.24元，较上市价16元，低2.76元或17%，成交1,107万股，涉资1.43亿元。不计手续费，每手500股，账面蚀1,380元。创胜是一家集发现、研发、制造及业务拓展能力为一体临床阶段生物制药公司，管理团队主要业务(包括临床开发、监管准入及业务拓展)位於中国及美国。集团利用高效监管...</p>\n\n<a href=\"http://www.aastocks.com/apps/data/iphone/news/newscontent.aspx?newsid=NOW.1132352&style=5&chgstyle=1&categoryid=stock&width=320&market_id=hk&fontary=3&platform=iPhone&language=sc&isfirstreq=1&sourceid=aafn&datatype=0\">网页链接</a>\n\n</div>\n","source":"aastocks","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>《新股表现》创胜(06628.HK)收13.24元低上市价17%  每手账面蚀1,380元</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n《新股表现》创胜(06628.HK)收13.24元低上市价17%  每手账面蚀1,380元\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-29 16:14 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.aastocks.com/apps/data/iphone/news/newscontent.aspx?newsid=NOW.1132352&style=5&chgstyle=1&categoryid=stock&width=320&market_id=hk&fontary=3&platform=iPhone&language=sc&isfirstreq=1&sourceid=aafn&datatype=0><strong>AAFN</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>创胜集团-B  首日挂牌，股价持续「潜水」，今天低开18.8%报13元，高低见13.34/12.08元，全日收13.24元，较上市价16元，低2.76元或17%，成交1,107万股，涉资1.43亿元。不计手续费，每手500股，账面蚀1,380元。创胜是一家集发现、研发、制造及业务拓展能力为一体临床阶段生物制药公司，管理团队主要业务(包括临床开发、监管准入及业务拓展)位於中国及美国。集团利用高效监管...</p>\n\n<a href=\"http://www.aastocks.com/apps/data/iphone/news/newscontent.aspx?newsid=NOW.1132352&style=5&chgstyle=1&categoryid=stock&width=320&market_id=hk&fontary=3&platform=iPhone&language=sc&isfirstreq=1&sourceid=aafn&datatype=0\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06628","symbol_name":"创胜集团-B","start_time":0,"source_url":"http://www.aastocks.com/apps/data/iphone/news/newscontent.aspx?newsid=NOW.1132352&style=5&chgstyle=1&categoryid=stock&width=320&market_id=hk&fontary=3&platform=iPhone&language=sc&isfirstreq=1&sourceid=aafn&datatype=0","article_id":"2171298543","we_media_id":null,"thumbnails":["https://static.tigerbbs.com/6ad7ed6b96b448ffcc5b5501b0dc346c"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2171298543","pubTimestamp":1632903254,"sourceInfo":{"source_id":"aastocks","name":"阿思达克财经"},"weMediaInfo":null,"summary":"创胜集团-B  首日挂牌，股价持续「潜水」，今天低开18.8%报13元，高低见13.34/12.08元，全日收13.24元，较上市价16元，低2.76元或17%，成交1,107万股，涉资1.43亿元。不计手续费，每手500股，账面蚀1,380元。创胜是一家集发现、研发、制造及业务拓展能力为一体临床阶段生物制药公司，管理团队主要业务位於中国及美国。集团利用高效监管审批路径以加快进行在美国研究用新药申请与前期临床试验，以及推进在中国来自庞大患者人群的巨大医疗需求缺口适应症临床试验。","collect":0,"end_time":0,"defaultTopTitle":"aastocks.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"06628":"创胜集团-B"},"translate_title":"[Performance of new shares] Chuangsheng (06628. HK) closed at 13.24 yuan, 17% of the low market price, and the book loss per hand was 1,380 yuan","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06628":1},"content_text":"创胜集团-B  首日挂牌，股价持续「潜水」，今天低开18.8%报13元，高低见13.34/12.08元，全日收13.24元，较上市价16元，低2.76元或17%，成交1,107万股，涉资1.43亿元。不计手续费，每手500股，账面蚀1,380元。创胜是一家集发现、研发、制造及业务拓展能力为一体临床阶段生物制药公司，管理团队主要业务(包括临床开发、监管准入及业务拓展)位於中国及美国。集团利用高效监管审批路径以加快进行在美国研究用新药(IND)申请与前期临床试验，以及推进在中国来自庞大患者人群的巨大医疗需求缺口适应症临床试验。创胜是次上市共发售4,033万股，并已引入亚洲生命科学投资公司LAV Amber、新加坡淡马锡、卡塔尔投资局旗下QIA及国企结构调整基金4名基石投资者，合共认购2,808.3万股；其中10%公开发售获近60倍超购，已启动回拨机制占比增至40%，认购一手中签率15%；股份以招股范围(15.8-16元)上限定价，料集资净额约5.744亿元，主要用作管线候选产品研发、为进行中及计划中临床与临床前试验、筹备注册备案和其他与商业化四款主打产品有关步骤或活动拨资；以及用作扩充管线和开发技术业务发展等。上市联席保荐人分别为高盛及中金。(sz/t)~阿思达克财经新闻网址: www.aastocks.com","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2171298543"}